Biophytis falls as COVID-19 impacts lead drug clinical program

Biophytis SA

07/04/2022 13:12

** U.S.-listed shares of France-based biotech co  BPTS.O 
fall ~15% to $2.14 premarket
    ** Co says patient recruitment has been terminated early for
its study testing lead drug candidate Sarconeos in COVID-19
patients due to global drop in hospitalizations  urn:newsml:reuters.com:*:nASM0006WN
    ** Co plans to report study results by Q3 2022
    ** In ongoing mid-stage study of the drug in Sarcopenia, a
muscle loss disorder, fewer patients could perform an
end-of-treatment test, which was study's main goal, due to
restrictions during the pandemic
    ** This resulted in 55% of loss of efficacy data
    ** Planned study of Sarconeos in patients with Duchenne
Muscular Dystrophy has been delayed to end of 2022 or beginning
of 2023, due to COVID-19 and its impact on operational
capabilities - BPTS
    ** Stock down ~53% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))